MLANA-loaded nanoparticle vaccine plus mAbs against PD-1 and OX40 to sensitize melanoma to Imbruvica

INDICATION: Melanoma

Immunization with an MLANA-loaded nanoparticle vaccine in combination with mAbs against PD-1 and OX40 could sensitize melanomas to Imbruvica ibrutinib. The vaccine consists of polylactic-co-glycolic acid polymer nanoparticles loaded with the melanoma-associated antigen MLANA and linked to mannose to target the therapy to antigen-presenting dendritic cells. In a mouse model of melanoma, triple combination therapy comprising the vaccine, the mAbs and Imbruvica reduced tumor volume and led to 67% survival, while dual therapy with the mAbs plus either Imbruvica or the vaccine led to 23% and 7% survival, respectively...